Huge unmet need SLBST Pharma is targeting endometriosis, a large patient population with limited effective treatments, creating a high-potential market for a non-hormonal, disease-modifying therapy and speed to market through an FDA-indicated pain relief label.

Phase 2 readiness FDA has green-lighted a Phase 2 dose-finding study, presenting a near-term opportunity to engage clinical development partners, contract research organizations, and potential co-development or licensing discussions around later-stage trials and regulatory milestones.

Intellectual property There are issued and pending patents protecting the novel indication, enabling defensible positioning for partnerships, licensing deals, and exclusive access in key geographies.

Safety and mechanism Using a reformulated hydroxychloroquine with a dual mechanism to reduce inflammation and autophagy offers a compelling value proposition for partnerships focused on safer, non-surgical management and reduced need for opioids and GnRH therapies.

Early-stage traction With a current revenue range and a small team, there is an opportunity to pursue strategic collaborations with larger biopharma for capital, manufacturing, late-stage development, and commercialization planning to accelerate market entry.